CreoSG크레오에스지

CreoSG remains loss-making with heavy debt, and its share price has fallen sharply over the past year.

CreoSG is a small Korean IT services company with financial software, bio and real estate businesses. On trailing twelve-month figures to H1 2026 it had revenue of ₩11.9B... as reported in won terms of ₩11.9B, but an operating loss of ₩3.8B and a net loss of ₩3.2B, with borrowings of ₩31.6B against cash of ₩0.4B. The share price closed at ₩2,590 on 2026-10-27, down 26.5% over one year and 60.8% over three months.

What stands out

• Revenue has been broadly flat to rising over recent years, reaching ₩10.9B in 2025, but operating losses have persisted every year since 2021, with a 2025 operating margin of -59%.
• Liabilities are 92.2% of equity and free cash flow over the trailing period was negative ₩2.2B, so the balance sheet relies heavily on borrowings.
• The bio business is described as generating no revenue, so the company's earnings depend on its software and IT services segments and its real estate operation.
• Recent filings are mostly ownership-related, including several largest-shareholder change amendments and 5%+ holding reports, plus an acquisition of shares in another company (Q-Holdings) for about ₩8.1B.
• Foreign ownership is recorded at 0%, and the company has no dividend yield; the data does not include analyst ratings or price targets.

What to watch

• Next periodic results and whether the operating loss narrows from the trailing figures of about -₩3.8B.
• Follow-up on the loan provision decision and the rights offering involving Curo Holdings, which the data does not explain in detail.
• Further largest-shareholder change filings and any commercial progress or regulatory steps for the vaccine patent, which the data does not quantify.